PPMS

Oct. 4 Online Conference Offers Latest Insights Into Progressive MS

An upcoming conference focused on progressive multiple sclerosis (MS) will offer the latest insights about the underlying biology of the disease, and treatment and clinical strategies in development. The one-day conference, “Emerging Research & Trial Strategies for Progressive Multiple Sclerosis,” is taking place virtually on Oct. 4,and is…

MD1003 Aids Walking Speed in Progressive MS, But Carries Risks

High-dose biotin aided walking speed in people with progressive multiple sclerosis after 12 to 15 months as an add-on treatment, an analysis of placebo-controlled clinical trials shows. However, the therapy failed to improve other measures of disability, and was associated with inaccurate lab test results caused by high levels…

Trials of IMU-838 in RRMS, Progressive MS Start Later This Year

The U.S. Food and Drug Administration has cleared Immunic Therapeutics to initiate two clinical trials of its investigational medicationĀ IMU-838 (vidofludimus calcium) in people with relapsing-remitting multiple sclerosis (RRMS), as well as a separate trial for people with progressive types of MS. The RRMS clinical trial program, expected…

#AANAM – Early Ocrevus Treatment Helps to Protect Nervous System

Editorā€™s note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17ā€“22. GoĀ hereĀ to read the latest stories from the conference. TreatingĀ multiple sclerosis (MS) in its earlier stages with Ocrevus (ocrelizumab) can substantially lower disease activity and lessen damage…

Ocrevus May Delay by 7 Years PPMS Patients’ Need for Wheelchair

Ocrevus (ocrelizumab) treatment may delay the need for a wheelchair by seven years in patients with primary progressive multiple sclerosisĀ (PPMS), a study reports. This delay, drawn from clinical trial data on treatment- versus placebo-group patients and supported by real-world findings, likely translates to long-term benefits for PPMS patients,…

SERPINA3 Nerve Injury-induced Protein May Be Biomarker of PPMS

People with primary progressive multiple sclerosis (PPMS) have significantly higher levels of a nerve injury-induced protein, called SERPINA3, in the cerebrospinal fluid (CSF) than do those with relapsing-remitting MS (RRMS) and those without the neurodegenerative disease, a study shows. Of note, the CSF is the liquid that bathes…

#MSVirtual2020 – Masitinib Delays Disability Progression in PPMS, Non-active SPMS

AB Scienceā€™s lead candidate masitinibĀ safely and effectively delays disability progression in people withĀ primary progressive multiple sclerosisĀ (PPMS) and non-activeĀ secondary progressive MSĀ (SPMS), according to top-line data from a clinical trial. The therapy was found to significantly lower the risk of first and confirmed (three-month) disability progression, and to reduce…

Scottish Medicines Consortium Approves Ocrevus for Treating PPMS

Ocrevus (ocrelizumab) has been approved in Scotland as a treatment for early, inflammatory primary progressive multiple sclerosis (PPMS). The Scottish Medicines Consortium (SMC) has advised that OcrevusĀ can be prescribed by the National Health Service (NHS) forĀ people with PPMS who have had symptoms for less than 15…

#ECTRIMS2019 – Is Rituximab a Reasonable Option for MS Patients?

Editorā€™s note: This is the first story in a three-part report examining the question, ā€œIs rituximab a reasonable alternative treatment for MS?ā€, which was a topic discussed at this yearā€™s Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Here, we provide a synopsis of…